Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

医学 重症肌无力 耐受性 不利影响 抗原 内科学 胃肠病学 免疫学
作者
Volkan Granit,Michael Benatar,Metin Kurtoğlu,Miloš D Miljković,Nizar Chahin,Gregory Sahagian,Marc H Feinberg,Adam Slansky,Tuan Vu,Christopher M. Jewell,Michael S. Singer,Murat V. Kalayoglu,James F. Howard,Tahseen Mozaffar,Volkan Granit,Michael Benatar,Tahseen Mozaffar,Nizar Chahin,James F. Howard,Adam D Slansky,Marc H Feinberg,Gregory Sahagian,Tuan Vu,Denise Pereira,Julie Steele,Marcelo Paredes,Cara L. Benjamin,Krishna V. Komanduri,Thomas H. Brannagan,Joan Fong,Luis de la Cruz,Diana Dimitrova,Manisha Chopra,Keith E. Holley,Gabrielle DeMaria,Antonio Tenorio,Naraly Requena,Benjamin Brooks,Niraja Suresh,Jerrica Farias,Miloš D Miljković,Metin Kurtoğlu,M. Casi,Abhijit Chowdhury,Hafsa Kamboh,Charles A. Stewart,Mehmet Tosun,Yulong Shang,Matthew T Duverney,Maria L. Kireeva,Emily English,Christopher Jewell,Michael S. Singer,Murat V. Kalayoglu
出处
期刊:Lancet Neurology [Elsevier]
卷期号:22 (7): 578-590 被引量:28
标识
DOI:10.1016/s1474-4422(23)00194-1
摘要

Chimeric antigen receptor (CAR) T cells are highly effective in treating haematological malignancies, but associated toxicities and the need for lymphodepletion limit their use in people with autoimmune disease. To explore the use of CAR T cells for the treatment of people with autoimmune disease, and to improve their safety, we engineered them with RNA (rCAR-T)-rather than the conventional DNA approach-to target B-cell maturation antigen (BCMA) expressed on plasma cells. To test the suitability of our approach, we used rCAR-T to treat individuals with myasthenia gravis, a prototypical autoantibody disease mediated partly by pathogenic plasma cells.MG-001 was a prospective, multicentre, open-label, phase 1b/2a study of Descartes-08, an autologous anti-BCMA rCAR-T therapy, in adults (ie, aged ≥18 years) with generalised myasthenia gravis and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or higher. The study was done at eight sites (ie, academic medical centres or community neurology clinics) in the USA. Lymphodepletion chemotherapy was not used. In part 1 (phase 1b), participants with Myasthenia Gravis Foundation of America (MGFA) disease class III-IV generalised myasthenia gravis received three ascending doses of Descartes-08 to determine a maximum tolerated dose. In part 2 (phase 2a), participants with generalised myasthenia gravis with MGFA disease class II-IV received six doses at the maximum tolerated dose in an outpatient setting. The primary objective was to establish safety and tolerability of Descartes-08; secondary objectives were to assess myasthenia gravis disease severity and biomarkers in participants who received Descartes-08. This trial is registered with clinicaltrials.gov, NCT04146051.We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score (n=1) or lack of generalised disease (n=1). Median follow-up in part 2 was 5 months (range 3-9 months). There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity. Common adverse events were headache (six of 14 participants), nausea (five of 14), vomiting (three of 14), and fever (four of 14), which resolved within 24 h of infusion. Fevers were not associated with increased markers of cytokine release syndrome (IL-6, IL-2, and TNF). Mean improvements from baseline to week 12 were -6 (95% CI -9 to -3) for MG-ADL score, -7 (-11 to -3) for Quantitative Myasthenia Gravis score, -14 (-19 to -9) for Myasthenia Gravis Composite score, and -9 (-15 to -3) for Myasthenia Gravis Quality of Life 15-revised score.In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases.Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gz完成签到,获得积分10
3秒前
郁盈完成签到,获得积分10
3秒前
啥时候吃火锅完成签到 ,获得积分10
5秒前
Murray完成签到,获得积分10
5秒前
肉肉的小屋完成签到,获得积分10
5秒前
Lucas完成签到,获得积分10
6秒前
cxlhzq完成签到,获得积分10
9秒前
半夏完成签到 ,获得积分10
10秒前
wen完成签到,获得积分10
10秒前
郭星星完成签到,获得积分10
13秒前
上官若男应助里涵采纳,获得10
13秒前
panfan完成签到,获得积分10
13秒前
潜山耕之完成签到,获得积分10
14秒前
aaaaaa发布了新的文献求助10
14秒前
醉熏的不凡完成签到 ,获得积分10
14秒前
慕容绝义完成签到,获得积分10
17秒前
虚幻采枫完成签到,获得积分10
17秒前
Yuri完成签到,获得积分10
18秒前
长安完成签到,获得积分10
18秒前
123完成签到,获得积分10
18秒前
去码头整点薯条关注了科研通微信公众号
18秒前
ll完成签到,获得积分10
19秒前
Hello应助General采纳,获得10
19秒前
mito完成签到,获得积分10
20秒前
20秒前
卖鱼的高启强完成签到,获得积分10
20秒前
风中的怜阳完成签到,获得积分10
20秒前
美好的跳跳糖完成签到,获得积分10
21秒前
言文言完成签到,获得积分10
21秒前
张文静完成签到,获得积分10
21秒前
大模型应助aaaaaa采纳,获得10
21秒前
拼搏依玉完成签到,获得积分10
22秒前
元宝完成签到 ,获得积分10
23秒前
里涵完成签到,获得积分10
23秒前
23秒前
123发布了新的文献求助10
24秒前
再见了星空完成签到,获得积分10
24秒前
25秒前
xly完成签到,获得积分10
25秒前
Bordyfan完成签到 ,获得积分10
26秒前
高分求助中
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Cross-Cultural Psychology: Critical Thinking and Contemporary Applications (8th edition) 800
Counseling With Immigrants, Refugees, and Their Families From Social Justice Perspectives pages 800
マンネンタケ科植物由来メロテルペノイド類の網羅的全合成/Collective Synthesis of Meroterpenoids Derived from Ganoderma Family 500
岩石破裂过程的数值模拟研究 500
Electrochemistry 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2374255
求助须知:如何正确求助?哪些是违规求助? 2081583
关于积分的说明 5216917
捐赠科研通 1809257
什么是DOI,文献DOI怎么找? 902952
版权声明 558406
科研通“疑难数据库(出版商)”最低求助积分说明 482119